The results bring Eli Lilly’s pill orforglipron one step closer to becoming a new, needle-free alternative in the booming weight loss and diabetes market.
Related Posts
Stock futures are little changed after positive start to the holiday trading week: Live updates
The major averages posted modest gains on Monday to begin the holiday-shortened trading week.
Trump’s tariffs push will hit the U.S. harder than Europe in the short term, Santander chair says
“On a relative basis, in the short term, Europe will be less affected than the U.S.,” Santander’s Ana Botín said regarding President Donald Trump’s tariffs.
Procter & Gamble earnings beat estimates as shoppers buy more household staples
Procter & Gamble beat quarterly earnings and revenue estimates and also reiterated its fiscal 2025 forecast.